Skip to main content
Molecule ProfilePublished

Durvalumab

Durvalumab molecule page image

Durvalumab is a human monoclonal antibody belonging to the immune checkpoint inhibitor class of anticancer medicines. It specifically targets programmed death-ligand 1 (PD-L1), a protein expressed on certain cancer cells and immune cells that helps tumours evade immune surveillance. By binding to PD-L1 and blocking its interaction with programmed death-1 (PD-1) and CD80 receptors, durvalumab helps restore the activity of T lymphocytes against cancer cells. This immune-mediated mechanism can improve the body's ability to recognise and attack malignant cells. Durvalumab is administered through intravenous infusion and is used either as monotherapy or in combination with chemotherapy and other anticancer agents, depending on the cancer type and treatment setting. It has an important role in the management of selected patients with non-small cell lung cancer, small cell lung cancer, biliary tract cancer, hepatocellular carcinoma, endometrial cancer, and other approved malignancies. Unlike conventional chemotherapy, durvalumab works by modifying immune checkpoint signalling rather than directly targeting rapidly dividing cells. However, its immune-stimulating activity can also cause inflammation in healthy organs, requiring appropriate monitoring during treatment.

Linked Products

2

FAQs

7

References

3

Overview

Durvalumab is a human monoclonal antibody belonging to the immune checkpoint inhibitor class of anticancer medicines. It specifically targets programmed death-ligand 1 (PD-L1), a protein expressed on certain cancer cells and immune cells that helps tumours evade immune surveillance. By binding to PD-L1 and blocking its interaction with programmed death-1 (PD-1) and CD80 receptors, durvalumab helps restore the activity of T lymphocytes against cancer cells. This immune-mediated mechanism can improve the body's ability to recognise and attack malignant cells. Durvalumab is administered through intravenous infusion and is used either as monotherapy or in combination with chemotherapy and other anticancer agents, depending on the cancer type and treatment setting. It has an important role in the management of selected patients with non-small cell lung cancer, small cell lung cancer, biliary tract cancer, hepatocellular carcinoma, endometrial cancer, and other approved malignancies. Unlike conventional chemotherapy, durvalumab works by modifying immune checkpoint signalling rather than directly targeting rapidly dividing cells. However, its immune-stimulating activity can also cause inflammation in healthy organs, requiring appropriate monitoring during treatment.

Background and Date of Approval

Durvalumab was developed by AstraZeneca as a selective human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody targeting PD-L1. Its development followed advances in understanding the PD-1/PD-L1 immune checkpoint pathway and its role in tumour immune evasion. The molecule was initially investigated in advanced solid tumours and subsequently evaluated through several clinical trial programmes. The US Food and Drug Administration (FDA) granted its first approval in May 2017 for selected patients with locally advanced or metastatic urothelial carcinoma, followed by approval in February 2018 for unresectable stage III non-small cell lung cancer after chemoradiotherapy. The European Medicines Agency (EMA) granted marketing authorisation on 21 September 2018. Important clinical programmes include PACIFIC for stage III non-small cell lung cancer, CASPIAN for extensive-stage small cell lung cancer, TOPAZ-1 for biliary tract cancer, HIMALAYA for hepatocellular carcinoma, and subsequent studies evaluating its use in earlier-stage and additional cancer settings. Regulatory approvals have expanded over time to include selected lung, liver, biliary tract, endometrial, bladder, and gastric or gastro-oesophageal junction cancers. The approved indications and treatment combinations vary by country and are subject to local regulatory guidance.

Uses

Durvalumab is used for the treatment of several malignancies, depending on the patient's disease stage, tumour characteristics, previous treatment, and applicable regulatory approval. In non-small cell lung cancer, it is used as consolidation therapy in eligible patients with unresectable stage III disease that has not progressed following concurrent platinum-based chemoradiotherapy. It is also used in selected resectable cases as part of perioperative treatment involving platinum-based chemotherapy, and in metastatic disease in combination with tremelimumab and platinum-based chemotherapy for eligible patients. In extensive-stage small cell lung cancer, durvalumab is used with etoposide and platinum-based chemotherapy as first-line treatment. For unresectable or metastatic biliary tract cancer, it is administered with gemcitabine and cisplatin. In advanced or unresectable hepatocellular carcinoma, it may be used alone or with tremelimumab as first-line treatment. Depending on regional approvals, additional indications include selected patients with primary advanced or recurrent endometrial cancer, muscle-invasive bladder cancer, and resectable gastric or gastro-oesophageal junction adenocarcinoma. Treatment may involve monotherapy, combination chemotherapy, or other immunotherapy agents. Patient selection should follow the approved indication and relevant tumour-specific clinical assessment.

Administration

Durvalumab is administered as an intravenous infusion by healthcare professionals experienced in cancer immunotherapy. The infusion is generally administered over approximately 60 minutes after appropriate dilution, although administration instructions may vary according to the approved formulation and prescribing information. For adult patients, commonly used monotherapy schedules include 1,500 mg every four weeks in eligible patients weighing at least 30 kg, or weight-based dosing of 10 mg/kg or 20 mg/kg at specified intervals, depending on the indication and approved regimen. Certain treatment protocols use 1,500 mg every three weeks in combination with chemotherapy, followed by maintenance administration every four weeks. In hepatocellular carcinoma, combination treatment with tremelimumab may involve a single initial dose of tremelimumab alongside durvalumab, followed by durvalumab maintenance. In perioperative cancer treatment, dosing schedules depend on the neoadjuvant and adjuvant treatment phases. Duration varies by indication and may continue until disease progression, unacceptable toxicity, or a protocol-defined maximum treatment period, commonly up to 12 or 24 months in certain settings. Dose reductions are generally not recommended for immune checkpoint inhibitors; treatment interruption or permanent discontinuation is considered for significant adverse reactions. Patients should receive treatment in an appropriately equipped clinical setting with monitoring for infusion reactions and immune-mediated toxicities.

Side Effects

Common side effects of durvalumab include fatigue, weakness, nausea, decreased appetite, cough, diarrhoea, skin rash, itching, constipation, and musculoskeletal discomfort. Patients receiving durvalumab with chemotherapy may experience additional adverse effects associated with the accompanying anticancer medicines, including anaemia, reduced blood cell counts, nausea, vomiting, and changes in liver function. Some patients may develop mild infusion-related reactions, including fever, chills, headache, or flushing during or shortly after administration. Immune-related inflammation can affect the thyroid gland, lungs, liver, intestines, skin, and other organs. Thyroid dysfunction may present as fatigue, changes in body weight, or altered heart rate. The frequency and severity of side effects vary according to the treatment regimen, disease condition, and individual immune response. Many adverse effects can be managed with supportive treatment and regular clinical assessment. Persistent or worsening symptoms should be reported promptly to the treating healthcare professional.

Warnings

Durvalumab can cause serious immune-mediated adverse reactions because of its mechanism of action. Important complications include immune-mediated pneumonitis, hepatitis, colitis, nephritis, thyroid disorders, adrenal insufficiency, hypophysitis, and type 1 diabetes mellitus. Severe skin reactions, myocarditis, neurological inflammation, and other rare immune-related complications may also occur. These reactions can develop during treatment or after treatment has been discontinued. Pneumonitis requires particular attention in patients with lung cancer or a history of thoracic radiotherapy because respiratory symptoms may overlap with existing disease or treatment-related complications. Liver function abnormalities should be evaluated promptly, particularly in patients with hepatocellular carcinoma or underlying liver disease. Severe immune-mediated reactions may require treatment interruption, permanent discontinuation, and systemic corticosteroid therapy or other immunosuppressive treatment. Infusion-related reactions, including severe hypersensitivity, may also require immediate medical intervention. Durvalumab can cause fetal harm and is generally not recommended during pregnancy. Patients should be counselled regarding reproductive precautions. Healthcare professionals should also consider the risk of complications associated with allogeneic haematopoietic stem cell transplantation performed before or after PD-1/PD-L1 checkpoint inhibitor treatment.

Precautions

Before starting durvalumab, healthcare professionals should assess the patient's medical history, cancer stage, previous anticancer treatments, autoimmune disorders, organ function, and baseline laboratory parameters. Baseline investigations generally include complete blood count, liver function tests, renal function tests, thyroid function, and other assessments according to the patient's clinical condition. Particular caution is required in patients with active autoimmune diseases, previous organ transplantation, interstitial lung disease, or a history of immune-mediated complications. Patients with hepatitis or other chronic infections may require additional assessment before treatment. Durvalumab should generally be avoided during pregnancy, and effective contraception is recommended during treatment and for the period specified in the applicable prescribing information after the last dose. Breastfeeding should also be avoided during treatment and for the recommended post-treatment period. Live vaccines should generally be avoided during active immunotherapy unless specifically advised by the treating specialist. Classic cytochrome P450-mediated drug interactions are uncommon because durvalumab is a monoclonal antibody and is not primarily metabolised through hepatic drug-metabolising enzymes. However, systemic immunosuppressants and corticosteroids may influence immune activity and should be used carefully, particularly when managing immune-related adverse reactions. Combining durvalumab with other anticancer agents requires appropriate assessment of overlapping toxicities.

Expert Tips

Before initiating durvalumab, prescribers should confirm the approved cancer indication, treatment stage, relevant biomarker or molecular testing requirements, and suitability of the proposed combination regimen. Baseline assessment should include thyroid function, liver enzymes, renal function, blood counts, and evaluation for pre-existing autoimmune or inflammatory conditions. Patients should be counselled about the possibility of delayed immune-mediated adverse reactions and instructed to report persistent cough, breathlessness, diarrhoea, abdominal pain, jaundice, unusual fatigue, severe skin reactions, or changes in urination. Regular laboratory monitoring should continue throughout treatment and should be adapted according to the patient's clinical condition. Pharmacists should verify the prescribed dose, infusion schedule, compatibility with accompanying chemotherapy, preparation requirements, and storage conditions. Durvalumab should be prepared and administered according to the manufacturer's approved handling instructions, with appropriate aseptic precautions. Prescribers should distinguish immune-related toxicities from cancer progression, infection, and chemotherapy-associated adverse effects. Early recognition and appropriate management of immune-mediated complications can help prevent severe organ damage. Coordination among oncologists, pharmacists, nurses, pulmonologists, endocrinologists, and other relevant specialists is important for safe treatment and continuity of care.

FAQs

What is Durvalumab?

Durvalumab is a human monoclonal antibody and PD-L1 immune checkpoint inhibitor used in the treatment of selected cancers. It helps the immune system recognise and attack cancer cells by blocking PD-L1 signalling.

How is Durvalumab administered?

Durvalumab is administered through intravenous infusion by trained healthcare professionals. Depending on the indication, it may be given alone or in combination with chemotherapy or other immunotherapy medicines.

What conditions is Durvalumab used for?

Durvalumab is used for selected cases of non-small cell lung cancer, small cell lung cancer, biliary tract cancer, hepatocellular carcinoma, endometrial cancer, bladder cancer, and other approved malignancies. The exact indications depend on regional regulatory approvals.

What are common side effects?

Common side effects include fatigue, nausea, diarrhoea, cough, skin rash, itching, decreased appetite, and musculoskeletal discomfort. Combination treatment may produce additional adverse effects.

What serious risks should be monitored?

Important risks include immune-mediated pneumonitis, hepatitis, colitis, nephritis, thyroid disorders, adrenal insufficiency, and severe infusion-related reactions. Prompt assessment is necessary when symptoms suggest immune-related organ inflammation.

How long is treatment continued?

Treatment duration depends on the cancer type, treatment setting, clinical response, and tolerability. It may continue until disease progression, unacceptable toxicity, or the maximum duration specified in the approved treatment regimen.

What monitoring is required during treatment?

Monitoring generally includes complete blood counts, liver and kidney function, thyroid function, respiratory symptoms, and signs of immune-mediated adverse reactions. Additional investigations may be required according to the patient's cancer type and treatment combination.

References

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s035lbl.pdf
  2. https://www.medicines.org.uk/emc/files/pil.9495.pdf
  3. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf

More Molecule Profiles

Browse other published molecule pages in the catalog.

Inactivated Influenza

Inactivated influenza vaccine (IIV) is a preventive vaccine used to protect against seasonal influenza, a contagious respiratory…

View molecule page

Dulaglutide

Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used to improve blood glucose control in people wit…

View molecule page

CYTOKINE REMOVAL

Cytokine removal is an extracorporeal blood-purification approach intended to reduce excessive concentrations of circulating cyto…

View molecule page